Helen Colhoun

List of Publications by Year
in descending order

251 papers	26,029 citations	8732 75 h-index	6979 154 g-index
269 all docs	269 docs citations	269 times ranked	27059 citing authors

#	Article	IF	Citations
1	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, The, 2004, 364, 685-696.	6.3	3,502
2	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
3	Problems of reporting genetic associations with complex outcomes. Lancet, The, 2003, 361, 865-872.	6.3	1,144
4	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174â€˜000 participants in 27 randomised trials. Lancet, The, 2015, 385, 1397-1405.	6.3	1,112
5	Association of LDL Cholesterol, Nonâ€"HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins. JAMA - Journal of the American Medical Association, 2012, 307, 1302.	3.8	650
6	Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events. Journal of the American College of Cardiology, 2014, 64, 485-494.	1.2	512
7	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	6.3	512
8	Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010. JAMA - Journal of the American Medical Association, 2015, 313, 37.	3.8	454
9	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
10	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics, 2011, 43, 117-120.	9.4	390
11	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, The, 2018, 392, 1311-1320.	6.3	355
12	Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2009, 52, 1755-1765.	2.9	351
13	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. European Heart Journal, 2015, 36, 1186-1194.	1.0	344
14	Socio-economic status and blood pressure: an overview analysis. Journal of Human Hypertension, 1998, 12, 91-110.	1.0	335
15	High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K.: A cohort study using the General Practice Research Database. Diabetes Care, 2006, 29, 798-804.	4.3	315
16	Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Journal of the American College of Cardiology, 2011, 57, 1535-1545.	1.2	305
17	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: THE ODYSSEY COMBO I study. American Heart Journal, 2015, 169, 906-915.e13.	1.2	294
18	Blood pressure screening, management and control in England. Journal of Hypertension, 1998, 16, 747-752.	0.3	278

#	Article	IF	Citations
19	Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study. PLoS Medicine, 2012, 9, e1001321.	3.9	270
20	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ, The, 2020, 371, m3582.	3.0	261
21	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes and Endocrinology,the, 2021, 9, 82-93.	5.5	251
22	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	5.5	248
23	Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia, 2011, 54, 3003-3006.	2.9	234
24	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. International Journal of Cardiology, 2014, 176, 55-61.	0.8	229
25	Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases, 2009, 54, 810-819.	2.1	227
26	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. PLoS Genetics, 2012, 8, e1002921.	1.5	216
27	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	5.8	216
28	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	5.5	207
29	All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia, 2006, 49, 660-666.	2.9	193
30	Biomarkers of diabetic kidney disease. Diabetologia, 2018, 61, 996-1011.	2.9	179
31	Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study. Clinical Pharmacology and Therapeutics, 2011, 89, 210-216.	2.3	177
32	The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia, 2010, 53, 809-820.	2.9	175
33	Mortality in people with Type 2 diabetes in the UK. Diabetic Medicine, 2006, 23, 516-521.	1.2	173
34	Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?. Diabetologia, 2013, 56, 1462-1470.	2.9	172
35	Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. PLoS Genetics, 2012, 8, e1002584.	1.5	166
36	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis, 2016, 244, 138-146.	0.4	163

#	Article	IF	Citations
37	Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients. Circulation, 2013, 128, 1504-1512.	1.6	162
38	Design and baseline characteristics of participants in the <scp>R</scp>esearching cardiovascular <scp>E</scp>vents with a <scp>W</scp>eekly <scp>IN</scp>cretin in <scp>D</scp>iabetes (<scp>REWIND</scp>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	2.2	160
39	Insight into the nature of the CRPâ€"coronary event association using Mendelian randomization. International Journal of Epidemiology, 2006, 35, 922-931.	0.9	159
40	Effect of Vaccination on Transmission of SARS-CoV-2. New England Journal of Medicine, 2021, 385, 1718-1720.	13.9	150
41	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney International, 2004, 65, 1790-1794.	2.6	149
42	The Association of Heart-Rate Variability With Cardiovascular Risk Factors and Coronary Artery Calcification: A study in type 1 diabetic patients and the general population. Diabetes Care, 2001, 24, 1108-1114.	4.3	146
43	Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes. Diabetes, 2011, 60, 2379-2385.	0.3	144
44	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. European Heart Journal, 2016, 37, 2981-2989.	1.0	142
45	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia, 2015, 58, 493-504.	2.9	140
46	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
47	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	1.2	137
48	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.3	136
49	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	3.0	135
50	Lipoprotein Subclasses and Particle Sizes and Their Relationship With Coronary Artery Calcification in Men and Women With and Without Type 1 Diabetes. Diabetes, 2002, 51, 1949-1956.	0.3	131
51	Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia, 2012, 55, 2929-2937.	2.9	128
52	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 2015, 36, 1536-1546.	1.0	126
53	Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney International, 2015, 88, 888-896.	2.6	124
54	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	4.9	123

#	Article	IF	Citations
55	The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. Journal of the American College of Cardiology, 2000, 36, 2160-2167.	1.2	118
56	Contemporary Risk of Hip Fracture in Type 1 and Type 2 Diabetes: A National Registry Study From Scotland. Journal of Bone and Mineral Research, 2014, 29, 1054-1060.	3.1	111
57	Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care, 2006, 29, 2378-2384.	4.3	108
58	Diabetes and pregnancy: national trends over a 15 year period. Diabetologia, 2018, 61, 1081-1088.	2.9	107
59	Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function. Circulation, 2003, 108, 678-683.	1.6	105
60	Efficacy and safety of alirocumab in insulin€treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM€INSULIN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2017, 19, 1781-1792.	2.2	105
61	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes and Endocrinology,the, 2014, 2, 481-487.	5.5	101
62	The Genetic Landscape of Renal Complications in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2017, 28, 557-574.	3.0	101
63	Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). Journal of Lipid Research, 2012, 53, 1000-1011.	2.0	97
64	Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia, 2006, 49, 2859-2865.	2.9	96
65	Reduced Incidence of Lower-Extremity Amputations in People With Diabetes in Scotland. Diabetes Care, 2012, 35, 2588-2590.	4.3	95
66	Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine, 2002, 19, 201-211.	1.2	92
67	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care, 2018, 41, 341-347.	4.3	92
68	Glycosylation of immunoglobulin G is regulated by a large network of genes pleiotropic with inflammatory diseases. Science Advances, 2020, 6, eaax0301.	4.7	90
69	Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1723-1731.	1.1	86
70	The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis, 2003, 167, 243-255.	0.4	85
71	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International, 2018, 93, 1397-1408.	2.6	83
72	Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia, 2012, 55, 2335-2342.	2.9	82

#	Article	IF	Citations
73	Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clinical Chemistry, 2009, 55, 473-480.	1.5	78
74	Paradoxical Lower Serum Triglyceride Levels and Higher Type 2 Diabetes Mellitus Susceptibility in Obese Individuals with the PNPLA3 148M Variant. PLoS ONE, 2012, 7, e39362.	1.1	78
75	Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population. Journal of the American College of Cardiology, 2001, 38, 1814-1820.	1.2	77
76	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	5.5	77
77	Alirocumab vs usual lipidâ€lowering care as addâ€on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DMâ€DYSLIPIDEMIA randomized trial. Diabetes, Obesity and Metabolism, 2018, 20, 1479-1489.	2.2	76
78	N-Glycan Profile and Kidney Disease in Type 1 Diabetes. Diabetes Care, 2018, 41, 79-87.	4.3	75
79	Risk factors for renal failure: The WHO multinational study of vascular disease in diabetes. Diabetologia, 2001, 44, S46-S53.	2.9	74
80	A genomeâ€wide association study suggests an association of <scp>C</scp>hr8p21.3 (<scp><i>GFRA2</i></scp>) with diabetic neuropathic pain. European Journal of Pain, 2015, 19, 392-399.	1.4	71
81	Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. Diabetologia, 2016, 59, 2106-2113.	2.9	71
82	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	1.6	71
83	A Genome-wide Association Study Provides Evidence of Sex-specific Involvement of Chr1p35.1 () Tj ETQq1 1 0.784314 rgBT /Overlock 1386-1393.	2.7	67
84	Blood pressure in women using oral contraceptives. Journal of Hypertension, 1997, 15, 1063-1068.	0.3	66
85	Effect of Socioeconomic Status on Mortality Among People With Type 2 Diabetes: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetes Care, 2011, 34, 1127-1132.	4.3	66
86	LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes. Diabetes Care, 2014, 37, 1643-1649.	4.3	66
87	Integration of genome-wide association studies with biological knowledge identifies six novel genes related to kidney function. Human Molecular Genetics, 2012, 21, 5329-5343.	1.4	64
88	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia, 2013, 56, 1716-1725.	2.9	64
89	Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. British Journal of Ophthalmology, 2014, 98, 790-795.	2.1	64
90	Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes. Diabetes, 2002, 51, 3300-3305.	0.3	63

#	Article	IF	Citations
91	Lipid Transfer Protein Activities in Type 1 Diabetic Patients Without Renal Failure and Nondiabetic Control Subjects and Their Association With Coronary Artery Calcification. Diabetes, 2001, 50, 652-659.	0.3	61
92	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. PLoS Medicine, 2020, 17, e1003374.	3.9	61
93	Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia, 2008, 51, 1639-1645.	2.9	60
94	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). International Journal of Epidemiology, 2018, 47, 380-381j.	0.9	59
95	Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: the EURODIAB IDDM Complications Study. Diabetic Medicine, 1999, 16, 41-48.	1.2	58
96	Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia, 2015, 58, 1363-1371.	2.9	57
97	Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2005, 48, 2482-2485.	2.9	55
98	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care, 2021, 44, 390-398.	4.3	55
99	Multiethnic Genome-Wide Association Study of Diabetic Retinopathy Using Liability Threshold Modeling of Duration of Diabetes and Glycemic Control. Diabetes, 2019, 68, 441-456.	0.3	54
100	Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM complications study. , 1998, 15, 418-426.		53
101	The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabetic Medicine, 1999, 16, 35-40.	1.2	53
102	C-Reactive Protein in Type 1 Diabetes and Its Relationship to Coronary Artery Calcification. Diabetes Care, 2002, 25, 1813-1817.	4.3	53
103	End-stage renal disease and survival in people with diabetes: a national database linkage study. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 127-134.	0.2	52
104	A genome‐wide association study suggests new evidence for an association of the NADPH Oxidase 4 (NOX4) gene with severe diabetic retinopathy in type 2 diabetes. Acta Ophthalmologica, 2018, 96, e811-e819.	0.6	52
105	Characterizing genetic variants for clinical action. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 93-104.	0.7	50
106	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004724.	0.9	50
107	Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes. Diabetologia, 2019, 62, 156-168.	2.9	50
108	Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresis. Journal of Lipid Research, 2004, 45, 1069-1076.	2.0	49

#	Article	IF	Citations
109	Factors associated with stillbirth in women with diabetes. Diabetologia, 2019, 62, 1938-1947.	2.9	49
110	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders, 2014, 14, 121.	0.7	48
111	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	4.3	47
112	Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis, 2002, 163, 363-369.	0.4	46
113	Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. Diabetic Medicine, 2019, 36, 718-725.	1.2	46
114	Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia, 2012, 55, 2938-2945.	2.9	45
115	Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification. Cardiovascular Diabetology, 2013, 12, 149.	2.7	45
116	Glycaemic control trends in people with type 1 diabetes in Scotland 2004â€"2016. Diabetologia, 2019, 62, 1375-1384.	2.9	45
117	The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes and Vascular Disease Research, 2008, 5, 177-183.	0.9	44
118	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia, 2013, 56, 1845-1855.	2.9	44
119	Changes in Endothelium-Dependent Vasodilatation andÎ± -Adrenergic Responses in Resistance Vessels during the Menstrual Cycle in Healthy Women1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2499-2504.	1.8	43
120	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Medicine, 2019, 17, 165.	2.3	43
121	Ecological analysis of collectivity of alcohol consumption in England: importance of average drinker. BMJ: British Medical Journal, 1997, 314, 1164-1164.	2.4	43
122	Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012â€"2014): a population-based observational study. Diabetologia, 2018, 61, 108-116.	2.9	42
123	Efficacy and Safety of Alirocumab as Addâ€on Therapy in Highâ€"Cardiovascularâ€Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies. Clinical Cardiology, 2014, 37, 597-604.	0.7	41
124	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	1.0	41
125	Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia, 2019, 62, 1616-1627.	2.9	41
126	Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study. BMC Medicine, 2021, 19, 51.	2.3	41

#	Article	IF	Citations
127	Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2007, 50, 733-740.	2.9	39
128	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. Diabetologia, 2012, 55, 2356-2360.	2.9	39
129	Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross‐sectional study. Journal of Internal Medicine, 2015, 278, 291-302.	2.7	38
130	After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet, The, 2005, 366, 1829-1831.	6.3	37
131	Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. BMC Cardiovascular Disorders, 2018, 18, 31.	0.7	36
132	Sharing a household with children and risk of COVID-19: a study of over 300 000 adults living in healthcare worker households in Scotland. Archives of Disease in Childhood, 2021, 106, 1212-1217.	1.0	36
133	Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes: A National Population-Based Retrospective Cohort Study. Diabetes Care, 2022, 45, 83-91.	4.3	36
134	Gender differences in accessing cardiac surgery across England: a cross-sectional analysis of the Health Survey for England. Social Science and Medicine, 1998, 47, 1773-1780.	1.8	34
135	Trends in hypertension management in Type I diabetes across Europe, 1989/1990 ? 1997/1999. Diabetologia, 2002, 45, 1362-1371.	2.9	33
136	Common Variants in Mendelian Kidney Disease Genes and Their Association with Renal Function. Journal of the American Society of Nephrology: JASN, 2013, 24, 2105-2117.	3.0	33
137	Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). Diabetologia, 2016, 59, 299-306.	2.9	33
138	The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia, 2019, 62, 621-632.	2.9	33
139	Achieved Levels of HbA1c and Likelihood of Hospital Admission in People With Type 1 Diabetes in the Scottish Population. Diabetes Care, 2011, 34, 1992-1997.	4.3	32
140	Metformin in adults with type 1 diabetes: <scp>D</scp>esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp>ascular <scp>A</scp>dverse <scp>L</scp>esions (<scp>REMOVAL</scp>): <scp>A</scp>n international multicentre trial. Diabetes, Obesity and Metabolism, 2017, 19, 509-516.	2.2	32
141	Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia, 2020, 63, 788-798.	2.9	31
142	Investigation of known estimated glomerular filtration rate loci in patients with Type 2 diabetes. Diabetic Medicine, 2013, 30, 1230-1235.	1.2	30
143	A genome-wide association study suggests that<i>MAPK14</i>is associated with diabetic foot ulcers. British Journal of Dermatology, 2017, 177, 1664-1670.	1.4	30
144	Ethnic Differences in Glycaemic Control in People with Type 2 Diabetes Mellitus Living in Scotland. PLoS ONE, 2013, 8, e83292.	1.1	30

#	Article	IF	Citations
145	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia, 2015, 58, 1494-1502.	2.9	29
146	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology, 2021, 20, 194.	2.7	29
147	Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment â€" systematic review and modelling of progression and cost-effectiveness. Health Technology Assessment, 2014, 18, 1-128.	1.3	29
148	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
149	Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study. Diabetes Care, 2018, 41, 2212-2219.	4.3	28
150	A noninvasive measure of baroreflex sensitivity without blood pressure measurement. American Heart Journal, 2002, 143, 441-447.	1.2	27
151	The impact of cardiovascular co-morbidities and duration of diabetes on the association between microvascular function and glycaemic control. Cardiovascular Diabetology, 2017, 16, 114.	2.7	27
152	Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis, 2018, 276, 124-130.	0.4	27
153	Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovascular Diabetology, 2019, 18, 149.	2.7	27
154	Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia, 2015, 58, 716-725.	2.9	26
155	Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. Diabetologia, 2019, 62, 418-425.	2.9	26
156	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study. BMC Medicine, 2021, 19, 149.	2.3	26
157	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2011, 54, 2000-2008.	2.9	25
158	Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). American Journal of Cardiology, 2017, 120, 931-939.	0.7	25
159	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 70.	2.7	25
160	Differences in HDL-cholesterol:apoA-I + apoA-II ratio and apoE phenotype with albuminuric status in Type I diabetic patients. Diabetologia, 2000, 43, 1353-1359.	2.9	24
161	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2Âyears. Journal of Clinical Lipidology, 2017, 11, 986-997.	0.6	24
162	Genome-Wide Association Study of Peripheral Artery Disease. Circulation Genomic and Precision Medicine, 2021, 14, e002862.	1.6	24

#	ARTICLE	IF	CITATIONS
163	Use of text-mining methods to improve efficiency in the calculation of drug exposure to support pharmacoepidemiology studies. International Journal of Epidemiology, 2018, 47, 617-624.	0.9	23
164	Risk of hospital admission with covid-19 among teachers compared with healthcare workers and other adults of working age in Scotland, March 2020 to July 2021: population based case-control study. BMJ, The, 2021, 374, n2060.	3.0	23
165	Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. Lancet Respiratory Medicine,the, 2022, 10, 566-572.	5.2	23
166	Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine, 2004, 21, 901-905.	1.2	22
167	Antibodies to periodontal pathogens and coronary artery calcification in type 1 diabetic and nondiabetic subjects. Journal of Periodontal Research, 2008, 43, 103-110.	1.4	22
168	Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia, 2020, 63, 636-647.	2.9	22
169	Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. Diabetes Care, 2020, 43, 734-742.	4.3	22
170	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. Cardiovascular Diabetology, 2020, 19, 14.	2.7	22
171	Development and validation of a cardiovascular risk prediction model in type 1 diabetes. Diabetologia, 2021, 64, 2001-2011.	2.9	22
172	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. Diabetes Therapy, 2018, 9, 1317-1334.	1.2	21
173	Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy, 2021, 12, 991-1028.	1.2	20
174	Development and Validation of a Path Length Calculation for Carotid–Femoral Pulse Wave Velocity Measurement. Hypertension, 2018, 71, 937-945.	1.3	19
175	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004–2013. Diabetic Medicine, 2018, 35, 99-106.	1.2	19
176	Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland. Diabetologia, 2021, 64, 1320-1331.	2.9	19
177	Confirmation needed for genes for hypertension. Lancet, The, 1999, 353, 1200-1201.	6.3	17
178	Effects of inaccuracies in arterial path length measurement on differences in MRI and tonometry measured pulse wave velocity. BMC Cardiovascular Disorders, 2017, 17, 118.	0.7	17
179	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17
180	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	5.5	17

#	Article	IF	Citations
181	A Genome-Wide Association Study Provides New Evidence That <i>CACNA1C</i> Gene is Associated With Diabetic Cataract. , 2016, 57, 2246.		16
182	Automated pathway and reaction prediction facilitates in silico identification of unknown metabolites in human cohort studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1071, 58-67.	1.2	16
183	A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care, 2021, 44, 901-907.	4.3	16
184	The effects of hormone replacement therapy on endothelial function in women with Turner's syndrome. Clinical Endocrinology, 2002, 56, 615-620.	1.2	15
185	Cause-specific mortality in Scottish patients with colorectal cancer with and without type 2 diabetes (2000–2007). Diabetologia, 2013, 56, 1531-1541.	2.9	15
186	Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). International Journal of Epidemiology, 2016, 46, dyw152.	0.9	15
187	Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial. Diabetes and Metabolism, 2017, 43, 453-459.	1.4	15
188	Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making. British Journal of Clinical Pharmacology, 2019, 85, 1907-1924.	1.1	15
189	Cross sectional study of differences in coronary artery calcification by socioeconomic status. BMJ: British Medical Journal, 2000, 321, 1262-1263.	2.4	14
190	Alirocumab Treatment and Achievement of Non–High–Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials. Journal of the American Heart Association, 2017, 6, .	1.6	14
191	Socio-economic status and mortality in people with type 1 diabetes in Scotland 2006–2015: a retrospective cohort study. Diabetic Medicine, 2020, 37, 2081-2088.	1.2	14
192	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	2.7	14
193	Cohort comparison study of cardiac disease and atherosclerotic burden in type 2 diabetic adults using whole body cardiovascular magnetic resonance imaging. Cardiovascular Diabetology, 2015, 14, 122.	2.7	13
194	Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes. BMC Cardiovascular Disorders, 2016, 16, 171.	0.7	13
195	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses. Journal of Clinical Lipidology, 2019, 13, 979-988.e10.	0.6	13
196	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 rgBT /Overlock 10	4.3	13
197	<i>PRF1</i> mutation alters immune system activation, inflammation, and risk of autoimmunity. Multiple Sclerosis Journal, 2021, 27, 1332-1340.	1.4	13
198	Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infectious Diseases, 2021, 21, 1275.	1.3	13

#	Article	IF	Citations
199	Status report of lipid-lowering trials in diabetes. Current Opinion in Lipidology, 2000, 11, 621-626.	1.2	12
200	Coronary heart disease in women: Why the disproportionate risk?. Current Diabetes Reports, 2006, 6, 22-28.	1.7	12
201	Type 2 diabetes, socioeconomic status and risk of cancer in Scotland 2001â€"2007. Diabetologia, 2013, 56, 1712-1715.	2.9	12
202	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 213-221.	0.9	12
203	Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. Atherosclerosis, 2018, 274, 182-190.	0.4	12
204	Use of personalised risk-based screening schedules to optimise workload and sojourn time in screening programmes for diabetic retinopathy: A retrospective cohort study. PLoS Medicine, 2019, 16, e1002945.	3.9	12
205	Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia, 2022, 65, 159-172.	2.9	12
206	Modelling the costâ€effectiveness of adopting riskâ€stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabetic Medicine, 2016, 33, 886-895.	1.2	11
207	Metformin and carotid intimaâ€media thickness in neverâ€smokers with type <scp>1</scp> diabetes: The <scp>REMOVAL</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1371-1378.	2.2	11
208	Effect of serum sample storage temperature on metabolomic and proteomic biomarkers. Scientific Reports, 2022, 12, 4571.	1.6	11
209	Continuous subcutaneous insulin infusion therapy is associated with reduced retinopathy progression compared with multiple daily injections of insulin. Diabetologia, 2021, 64, 1725-1736.	2.9	10
210	The effect of DAFNE education, continuous subcutaneous insulin infusion, or both in a population with type 1 diabetes in Scotland. Diabetic Medicine, 2020, 37, 1016-1022.	1.2	9
211	Biomarkers associated with early stages of kidney disease in adolescents with type 1 diabetes. Pediatric Diabetes, 2020, 21, 1322-1332.	1.2	9
212	Glucagon-Like PeptideÂ1 Receptor Agonist (GLP1RA) Exposure and Outcomes in TypeÂ2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy, 2021, 12, 969-989.	1.2	9
213	Insulin resistance-associated genetic variants in type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107842.	1.2	8
214	Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care, 2021, 44, 2010-2017.	4.3	8
215	Treatment of lipid disorders in patients with diabetes. Current Treatment Options in Cardiovascular Medicine, 2006, 8, 37-45.	0.4	7
216	Modelling cumulative exposure for inference about drug effects in observational studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1527-1533.	0.9	7

#	Article	IF	Citations
217	Whole body cardiovascular magnetic resonance imaging to stratify symptomatic and asymptomatic atherosclerotic burden in patients with isolated cardiovascular disease. BMC Medical Imaging, 2016, 16, 18.	1.4	6
218	Time trends in deaths before age 50 years in people with type 1 diabetes: a nationwide analysis from Scotland 2004–2017. Diabetologia, 2020, 63, 1626-1636.	2.9	6
219	Quantitative levels of serum *N*-glycans in type 1 diabetes and their association with kidney disease. Glycobiology, 2021, 31, 613-623.	1.3	6
220	CKMGlu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	5
221	Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus. Circulation Genomic and Precision Medicine, 2020, 13, e002769.	1.6	5
222	Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes. Diabetes, 2021, 70, 986-995.	0.3	5
223	The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes. Diabetologia, 2021, 64, 1309-1319.	2.9	5
224	Socio‐economic differences in cardiovascular disease risk factor prevalence in people with type 2 diabetes in Scotland: a cross‐sectional study. Diabetic Medicine, 2020, 37, 1395-1402.	1.2	4
225	The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information–Diabetes Collaboration. Diabetic Medicine, 2020, 37, 1927-1934.	1.2	4
226	Reservoir-Excess Pressure Parameters Independently Predict Cardiovascular Events in Individuals With Type 2 Diabetes. Hypertension, 2021, 78, 40-50.	1.3	4
227	Lipid goals in metabolic syndrome and diabetes. Current Atherosclerosis Reports, 2007, 9, 286-295.	2.0	3
228	Efficacy of COVID-19 vaccination in individuals designated as clinically extremely vulnerable in Scotland. F1000Research, 0, 10, 663.	0.8	2
229	356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Diabetes, 2020, 69, 356-OR.	0.3	2
230	Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland. Scandinavian Journal of Rheumatology, 2022, , 1-6.	0.6	2
231	Taking the V out of genes V environment. Journal of Human Hypertension, 1997, 11, 401-404.	1.0	1
232	The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease. British Journal of Diabetes and Vascular Disease, 2011, 11, 288-297.	0.6	1
233	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. Diabetologia, 2014, 57, 260-261.	2.9	1
234	Diabetes in Scotland: a rising tide. Lancet Diabetes and Endocrinology,the, 2020, 8, 375-376.	5.5	1

#	Article	IF	Citations
235	Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901â€"907. Diabetes Care, 2021, 44, e140-e141.	4.3	1
236	A life course approach to diabetes. , 2002, , 121-140.		1
237	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. Diabetes, 2020, 69, 924-P.	0.3	1
238	1615-P: Predicting End-Stage Kidney Disease in Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	1
239	Letters to the Editor. European Heart Journal, 1999, 20, 1515.	1.0	0
240	A novel common variant âˆ'181 G insertion in the promoter of the gene for phospholipid transfer protein. Atherosclerosis, 2005, 180, 211-213.	0.4	0
241	Eicosapentaenoic acid for prevention of major coronary events. Lancet, The, 2007, 370, 215.	6.3	0
242	Does Treating Hyperlipidaemia with Medication Prevent Complications?. , 0, , 241-255.		0
243	15â€¦Epicardial fat in diabetes mellitus and cardiovascular disease measured using cardiac magnetic resonance imaging: a summit substudy. Heart, 2015, 101, A5.3-A6.	1.2	0
244	John Fuller, 21 October 1937â€"2 July 2020. Diabetologia, 2020, 63, 2251-2252.	2.9	0
245	Microvascular disease in diabetes and severe COVID-19 outcomes â€" Authors' reply. Lancet Diabetes and Endocrinology,the, 2021, 9, 201.	5.5	0
246	490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial. Diabetes, 2020, 69, .	0.3	0
247	Title is missing!. , 2020, 17, e1003374.		0
248	Title is missing!. , 2020, 17, e1003374.		0
249	Title is missing!. , 2020, 17, e1003374.		0
250	Title is missing!. , 2020, 17, e1003374.		0
251	Title is missing!. , 2020, 17, e1003374.		0